Stifel Nicolaus Remains a Buy on Zimmer Biomet Holdings (ZBH)
Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Zimmer Biomet Holdings today and set a price target of $110.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Wise covers the Healthcare sector, focusing on stocks such as Boston Scientific, Edwards Lifesciences, and Outset Medical. According to TipRanks, Wise has an average return of -0.8% and a 48.40% success rate on recommended stocks.
In addition to Stifel Nicolaus, Zimmer Biomet Holdings also received a Buy from BTIG’s Ryan Zimmerman in a report issued on February 18. However, on March 2, Bank of America Securities maintained a Hold rating on Zimmer Biomet Holdings (NYSE: ZBH).
Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.24 billion and a net profit of $139.5 million. In comparison, last year the company earned a revenue of $2.02 billion and had a net profit of $239.5 million
Read More on ZBH:
Disclaimer & DisclosureReport an Issue
- Zimmer Biomet’s New Knee Implant Study Builds a Quiet Catalyst for Long-Term Growth
- Zimmer Biomet’s ROSA Knee v1.5 Pilot Study: What the Latest Update Signals for ZBH Investors
- Walmart downgraded, Etsy upgraded: Wall Street’s top analyst calls
- Zimmer Biomet initiated with a Market Perform at William Blair
- Zimmer Biomet’s New Stemless Shoulder Study Signals Strategic Push in Joint Reconstruction
